国药一致
(000028)
| 流通市值：110.54亿 | | | 总市值：128.69亿 |
| 流通股本：5.26亿 | | | 总股本：6.12亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 55,066,090,261.8 | 36,266,356,011.93 | 17,823,409,770.31 | 73,415,858,423.13 |
| 营业总成本 | 53,793,094,870.74 | 35,498,296,956.6 | 17,432,136,489.2 | 71,812,830,420.19 |
| 其他经营收益 | | | | |
| 营业利润 | 1,327,188,246.91 | 834,430,395.38 | 376,586,868.98 | 1,512,828,830.82 |
| 利润总额 | 1,316,989,893.91 | 827,384,868.33 | 376,860,528.73 | 1,509,020,328.67 |
| 净利润 | 1,015,950,276.74 | 647,798,030.55 | 305,160,963.77 | 1,128,348,677.76 |
| 每股收益 | | | | |
| 其他综合收益 | -6,177.6 | -6,177.6 | - | 1,970,509.18 |
| 综合收益总额 | 1,015,944,099.14 | 647,791,852.95 | 305,160,963.77 | 1,130,319,186.94 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 40,323,831,214.67 | 39,488,672,506.49 | 40,308,348,201.28 | 40,195,752,541.71 |
| 非流动资产: | | | | |
| 非流动资产合计 | 8,579,925,206.68 | 8,681,841,375.32 | 8,815,427,984.81 | 8,900,518,437.32 |
| 资产总计 | 48,903,756,421.35 | 48,170,513,881.81 | 49,123,776,186.09 | 49,096,270,979.03 |
| 流动负债: | | | | |
| 流动负债合计 | 25,440,772,708.37 | 25,003,503,533.79 | 25,897,591,583.51 | 26,105,142,816.61 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,203,097,654.95 | 1,272,733,625.19 | 1,313,481,025.09 | 1,366,643,608.91 |
| 负债合计 | 26,643,870,363.32 | 26,276,237,158.98 | 27,211,072,608.6 | 27,471,786,425.52 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 19,219,611,069 | 18,873,322,980.86 | 18,897,425,775.89 | 18,609,963,275.57 |
| 股东权益合计 | 22,259,886,058.03 | 21,894,276,722.83 | 21,912,703,577.49 | 21,624,484,553.51 |
| 负债和股东权益合计 | 48,903,756,421.35 | 48,170,513,881.81 | 49,123,776,186.09 | 49,096,270,979.03 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 59,227,044,847.48 | 39,000,345,475.91 | 17,348,365,372.1 | 78,834,075,364.34 |
| 经营活动现金流出小计 | 59,729,933,835.42 | 40,519,064,930.15 | 20,283,698,848.5 | 77,195,486,439.07 |
| 经营活动产生的现金流量净额 | -502,888,987.94 | -1,518,719,454.24 | -2,935,333,476.4 | 1,638,588,925.27 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 46,025,988.91 | 37,509,346.21 | 3,754,957.93 | 122,475,880.94 |
| 投资活动现金流出小计 | 94,436,036 | 59,415,362.07 | 26,970,163.32 | 225,400,701.72 |
| 投资活动产生的现金流量净额 | -48,410,047.09 | -21,906,015.86 | -23,215,205.39 | -102,924,820.78 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,587,312,263.18 | 1,273,235,673.11 | 767,158,810.65 | 1,761,780,819.6 |
| 筹资活动现金流出小计 | 3,118,065,020.32 | 1,732,540,269.37 | 434,764,302.19 | 3,124,007,020.96 |
| 筹资活动产生的现金流量净额 | -1,530,752,757.14 | -459,304,596.26 | 332,394,508.46 | -1,362,226,201.36 |
| 汇率变动对现金及现金等价物的影响 | 322,997.25 | 328,320.75 | -566.2 | -74,016.45 |
| 现金及现金等价物净增加额 | -2,081,728,794.92 | -1,999,601,745.61 | -2,626,154,739.53 | 173,363,886.68 |
| 期末现金及现金等价物余额 | 5,215,279,622.63 | 5,297,406,671.94 | 4,670,853,678.02 | 7,297,008,417.55 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -1,999,601,745.61 | - | 173,363,886.68 |
最新报告期：2026-10-21| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中金公司 | 夏璐,张琎,朱言音 | 1.99 | 2.19 | -- | 2026-10-21 |
| 华泰证券 | 代雯,孔垂岩,王殷杰 | 1.95 | 1.99 | 2.04 | 2026-08-29 |
| 中金公司 | 夏璐,张琎,朱言音 | 1.99 | 2.19 | -- | 2026-08-18 |